Collegium Pharmaceutical Q1 2024 Adj EPS $1.45 Beats $0.73 Estimate, Sales $144.923M Miss $146.853M Estimate
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2024 adjusted EPS of $1.45, surpassing the $0.73 estimate, marking a 98.63% beat and a 9.85% increase from last year's $1.32. However, their Q1 sales of $144.923M fell short of the $146.853M estimate by 1.31%, only slightly up by 0.11% from the previous year.
May 09, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical reported a significant beat on EPS estimates for Q1 2024 but missed slightly on sales forecasts.
The substantial beat on the EPS estimate is likely to have a positive impact on investor sentiment and the stock price in the short term, despite the slight miss on sales. The earnings per share figure often receives more attention as it directly relates to profitability and efficiency, potentially outweighing the minor sales shortfall in investors' eyes.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100